Prelude Therapeutics: Funding, Investors & Team (Oct 2026)
Prelude Therapeutics, established in 2016 by Krishna Vaddi, is a biotech company in Wilmington, Delaware. It focuses on creating innovative treatments that specifically target the factors driving cancer cell growth, survival, and resistance. By developing a range of orally bioavailable small-molecule therapies, Prelude Therapeutics aims to intervene at crucial points in the resistance pathways of cancer. Ultimately, their goal is to provide healthcare professionals with potential treatments that bring hope to individuals affected by cancer.
Prelude Therapeutics has raised $175M across 3 funding rounds on record, the most recent an undisclosed round of $90.0M announced in Apr 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Prelude Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Prelude Therapeutics Funding Rounds
Prelude Therapeutics raised $25.0M in an undisclosed round announced in Dec 2023.
1.9 years later, an undisclosed round of $60.0M was announced in Nov 2025.
5 months later, an undisclosed round of $90.0M was announced in Apr 2026.
Prelude Therapeutics Founders and Leadership Team
Contact details for the Prelude Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Prelude Therapeutics Funding Compared to Other Biotechnology Startups
Prelude Therapeutics' latest round of $90.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Prelude Therapeutics in Biotechnology and Wilmington
Companies Similar to Prelude Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Prelude Therapeutics Funding FAQs
What does Prelude Therapeutics do?
Prelude Therapeutics, established in 2016 by Krishna Vaddi, is a biotech company in Wilmington, Delaware. It focuses on creating innovative treatments that specifically target the factors driving cancer cell growth, survival, and resistance. By developing a range of orally bioavailable small-molecule therapies, Prelude Therapeutics aims to intervene at crucial points in the resistance pathways of cancer. Ultimately, their goal is to provide healthcare professionals with potential treatments that bring hope to individuals affected by cancer.
How much funding has Prelude Therapeutics raised?
Prelude Therapeutics has raised $175M across 3 rounds on record. The most recent is an undisclosed round of $90.0M announced in Apr 2026.
When did Prelude Therapeutics last raise funding?
Prelude Therapeutics' most recent funding round on record is an undisclosed round of $90.0M, announced in Apr 2026.
Who founded Prelude Therapeutics?
FundedIQ lists Kris Vaddi (Founder) at Prelude Therapeutics.
Who is the CEO of Prelude Therapeutics?
Krishna Vaddi is listed as CEO at Prelude Therapeutics.
Where is Prelude Therapeutics headquartered?
Prelude Therapeutics is based in Wilmington, Delaware, United States.
How many employees does Prelude Therapeutics have?
Prelude Therapeutics is in the 101-250 employee band.
How does Prelude Therapeutics' funding compare to other Biotechnology startups?
Prelude Therapeutics' latest round of $90.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Prelude Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Prelude Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.